<DOC>
	<DOCNO>NCT00005944</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug different way may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness second-look surgery without intraperitoneal infusion mitomycin fluorouracil treat patient colorectal cancer recurrent peritoneum .</brief_summary>
	<brief_title>Second-look Surgery With Without Intraperitoneal Chemotherapy Treating Patients With Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect second look surgery without intraperitoneal mitomycin fluorouracil 3 year survival rate patient colorectal cancer high risk peritoneal cavity cancer . II . Compare quality life patient treat regimen . III . Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord center , risk group , presence symptom ( yes v ) , isolated disease ( yes v ) . After primary surgery , patient receive 6 month chemotherapy consist leucovorin calcium IV follow fluorouracil IV 10 minute day 1-5 every 4 week . Patients undergo second look surgery laparoscopy 8-12 month . Second look surgery laparoscopy may perform early marker increase progressively unknown reason symptom peritoneal cancer occur . Patients recurrent disease resect randomized one two treatment arm . Patients residual disease unresectable disease follow survival . Arm I : Patients undergo complete resection detectable lesion follow immediately intraperitoneal ( IP ) mitomycin day 0 fluorouracil IP day 1-4 . Patients also receive systemic chemotherapy consist leucovorin calcium IV 2 hour fluorouracil IV bolus , follow fluorouracil IV 22 hour day 1 2 . Systemic chemotherapy repeat every 2 week 6 month . Arm II : Patients undergo complete partial resection receive systemic chemotherapy arm I . Quality life assess baseline every 4 month 3 year . All patient ( include nonrandomized patient ) follow every 4 month 3 year . PROJECTED ACCRUAL : A total 152 patient ( 76 randomize ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Primary diagnosis adenocarcinoma colon rectum meet one follow risk criterion primary surgery : Perforated bowel ( spontaneous ) Occlusion Peritoneal deposit Invasion serosa 4 cm diameter Concurrent ovarian metastasis Randomization eligibility : Presence proven recurrent peritoneal disease ( one micronodule 1 mm sufficient ) second look laparotomy Total resection macroscopic lesion possible ( local recurrence , lymph node hepatic metastasis ) PATIENT CHARACTERISTICS : Age : 70 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Creatinine great 1.4 mg/dL Cardiovascular : No cardiac condition would increase surgical risk Pulmonary : No pulmonary condition would increase surgical risk Other : No condition would increase surgical risk No malignancy within past 5 year except basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : No concurrent anticancer radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>